ArticleCureus2026
Combining Multiparametric Magnetic Resonance Imaging and Prostate-Specific Antigen Density in Selecting Patients for Prostate Biopsy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMultiparametric magnetic resonance imaging (mpMRI) combined with prostate-specific antigen density (PSAd) has emerged as an effective risk-stratification tool for guiding prostate biopsy decisions. This study aimed to determine the optimal, clinically feasible biopsy strategy by combining the mpMRI Prostate Imaging-Reporting and Data System (PI-RADS) score and PSAd to minimize unnecessary biopsies while maximizing the detection of clinically significant prostate cancer (csPCa; Gleason score {GS} ≥7), using transperineal targeted and systematic biopsy as the reference standard.
methodsWe retrospectively analyzed data from 511 men with clinical suspicion of prostate cancer (PCa) (PSA: >4 ng/mL; PI-RADS ≥3), who underwent pre-biopsy mpMRI and a subsequent combination of targeted and systematic transperineal prostate biopsy. Various mpMRI/PSAd thresholds were assessed based on their accuracy for detecting csPCa, their predictive value, the proportion of avoided biopsies, and net benefit and outcomes from decision curve analysis.
resultsThe overall analysis showed that the optimal strategy was to perform biopsy for lesions assessed as PI-RADS 4 and 5 or PI-RADS 3 lesions with PSAd of ≥0.15 ng/mL/mL. This combined approach yielded a negative predictive value (NPV) of 91% and a positive predictive value (PPV) of 43%. Implementing this strategy would have avoided biopsy in 16% (80/511) of the men and reduced the overdiagnosis of insignificant PCa by 9% (15/159) while missing only 4% (7/194) of csPCa cases.
conclusionCombining mpMRI with PSAd provides a robust, risk-stratified approach to PCa diagnosis. Men with equivocal mpMRI findings (PI-RADS 3) and low PSAd (<0.15 ng/mL/mL) may safely defer immediate prostate biopsy, reducing unnecessary procedures and the burden of overdiagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.